David Fajgenbaum

There is a massive gap in medicine that most people never see.

It is not caused by a lack of scientific discovery or a shortage of promising drugs. It is caused by incentives. When a medicine becomes generic, companies lose the ability to profit from proving new uses for it.

That means even if a low-cost drug could treat cancer, Alzheimer’s, or rare diseases, there is often no financial reason to run the clinical trial that would validate it.

A recent economic analysis estimates that this missing innovation is worth between $2.5 and $10 trillion in lost value.
Hundreds of potential treatments may already exist but remain unproven and unused because no one is incentivized to develop them.

was built to change that by systematically identifying these opportunities and helping bring them to patients.

Because we believe that no patient should suffer when there could be a potential treatment sitting on the pharmacy shelf.